Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of anti-HER3 monoclonal antibody GSK2849330 in advanced HER3-positive solid tumors
2013-001699-39Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GSK2849330 in Nonhematologic neoplasms and gastric cancer (GC), sponsored by GSK. Primary endpoint: Safety and tolerability. Started Feb 2015; status: completed.
02
Drugs
GSK2849330
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)
Beyond the preview
Go deeper on 2013-001699-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001699-39.